Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
22nd February 2021 | Emma Reeve | 6,260 | Exercise of derivative | $8.04 | $50,330.40 |
22nd February 2021 | Emma Reeve | 6,260 | Open or private sale | $37.60 | $235,373.50 |
19th February 2021 | Emma Reeve | 4,010 | Open or private sale | $37.71 | $151,217.90 |
19th February 2021 | Emma Reeve | 4,010 | Exercise of derivative | $8.04 | $32,240.40 |
18th February 2021 | Emma Reeve | 1,100 | Exercise of derivative | $8.04 | $8,844.00 |
18th February 2021 | Emma Reeve | 1,100 | Open or private sale | $37.58 | $41,343.06 |
17th February 2021 | Emma Reeve | 410 | Exercise of derivative | $8.04 | $3,296.40 |
17th February 2021 | Group L P Column | 10,000 | Open or private sale | $36.95 | $369,503.00 |
17th February 2021 | Emma Reeve | 410 | Open or private sale | $37.56 | $15,397.84 |
2nd February 2021 | Mark A Goldsmith | 5,000 | Exercise of derivative | $1.12 | $5,600.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel therapeutics in the field of epigenetics. Its product candidates include CPI-0610, CPI-1205, and CPI-0209.
28th February 2021
23rd February 2021